Last Updated on October 11, 2024 by The Health Master
Zydus Cadila has received tentative approval from the USFDA to market Osimertinib Tablets in the strengths of 40 mg and 80 mg (US RLD: Tagrisso Tablets). Osimertinib is used to treat lung cancer.
It belongs to a class of drugs known as kinase inhibitors. Osimertinib works by slowing or stopping the growth of cancer cells. It binds to a certain protein (epidermal growth factor receptor-EGFR) in some tumours.
The drug will be manufactured at the group’s formulation manufacturing facility at the SEZ, Ahmedabad. The group now has 318 approvals and has so far filed over 400 ANDAs since the commencement of the filing process in FY 2003-04.
Zydus Cadila gets USFDA nod for Fluphenazine HCL Tablets
Glenmark gets USFDA nod for Icatibant injection single-dose prefilled syringe
NATCO Pharma gets USFDA nod for Everolimus tablets
Natco Pharma gets USFDA nod for Lenalidomide capsules
Unichem Labs gets USFDA approval for Amitriptyline HCL Tablets
Alembic gets USFDA Final nod for Lurasidone HCL Tablets
Green signal: Moderna vaccines may soon be available in India
Drug alert: 23 out of 931 samples declared as NSQ in…
Govt issues operational guidelines for Pharma PLI scheme
USFDA accepts application from Lupin for Pegfilgrastim Biosimilar
Sun Pharma, Ferring Pharma sign agreement to launch CARITEC in India
Glenmark launches drug for the treatment of seizures
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
